-
EAU24 Interview | Dr. Matthew Galsky reports the OS results of the CheckMate 274 study for the first time, showing benefit trends from adjuvant immunotherapy
Dr. Matthew Galsky Icahn School of Medicine at Mount Sinai Tisch Cancer Institute Oncology Frontier：In recent years, research in the field of urothelial cancer has continued to make breakthroughs. Could…
-
EAU24 Interview | Dr. Jianming Guo and Dr. Riccardo Campi Discuss Renal Cancer Surgical Treatments
Dr. Jianming Guo Zhongshan Hospital Fudan University, Dept. of Urology, Shanghai, China Dr. Riccardo Campi Careggi Hospital, University of Florence, Florence, Italy Oncology Frontier: Both of you have had research…
-
SABCS Voice of China | Professors Qiang Liu and Yaping Yang: Final Results of the National Multicenter Clinical Study on AC*4 Sequential T*4 Combined with Full-Course Dual-Target Neoadjuvant Treatment for HER2-Positive Breast Cancer Disclosed
Led by Professor Qiang Liu and Professor Yaping Yang from the Sun Yat-sen Memorial Hospital’s Breast Tumor Hospital at Sun Yat-sen University, the final clinical study results of a new neoadjuvant treatment regimen for HER2-positive breast cancer were disclosed for the first time. The results were presented in the form of a POSTER at the…
-
SABCS Voice of China | Professor Jian Liu: A New Strategy for Treating HER2-Positive Advanced Breast Cancer in China
Currently, the combination of docetaxel, trastuzumab, and pertuzumab is the standard first-line treatment for HER2-positive metastatic breast cancer (MBC), but still, 60% of patients experience disease progression after 2 years of treatment. The second-line treatment standards include DS-8201, T-DM1, TKIs, etc., but these options still have their limitations and do not fully meet clinical treatment…
-
SABCS Voice of China | Teams led by Professors Yuanting Gu and Jingruo Li Announce Results of CDK4/6 Inhibitor Combined with Letrozole as Neoadjuvant Treatment for Early or Locally Advanced HR+/HER2- Breast Cancer
The results of a single-arm, multicenter, prospective exploratory clinical study on the neoadjuvant treatment of HR-positive, HER2-negative (HR+/HER2-) breast cancer with Dalpiciclib combined with Letrozole, led by Professor Yuanting Gu and Professor Jingruo Li from the First Affiliated Hospital of Zhengzhou University, were selected for poster presentation at the 2023 SABCS conference. The unveiling of…
-
SABCS 2023 | Professor Jiayi Chen : Escalating or De-escalating — Focusing on the Latest Developments in the Field of Breast Cancer Radiotherapy
The 46th San Antonio Breast Cancer Symposium (SABCS 2023) was held in San Antonio, Texas, where numerous significant studies were presented. Oncology Frontier had the privilege of inviting Professor Jiayi Chen from the Department of Radiation Oncology at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, to share the latest developments in…
-
SABCS Researchers Discuss丨Chemotherapy-Free Triple Combination for Advanced Triple-Positive Breast Cancer: HER2 Dual Antibody + CDK4/6i + Fulvestrant
Numerous studies have confirmed the therapeutic benefits of combining anti-HER2 therapy with endocrine treatment in patients with advanced triple-positive breast cancer (HR+/HER2+). With the enrichment of new endocrine targeting treatments and anti-HER2 treatment schemes in recent years, there has been exploration into other combination schemes, which are hopeful in providing more effective and less toxic…
-
SABCS Researchers Discuss | DEBBRAH Study: T-DXd Treatment for Leptomeningeal Metastatic Breast Cancer
The clinical treatment of breast cancer with leptomeningeal metastasis is extremely challenging, with patients surviving only a few months. Currently, intrathecal medication is the main treatment for leptomeningeal metastasis, but it comes with a high risk of bleeding and infection; finding effective systemic treatment drugs has been a hot topic of research in recent years.…
Connecting Medical Expertise through Media